报价延迟最少15分钟:2026/06/10 17:19 EDT
盘后时段
|
||||
|
1.43 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.43
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.55/-1.01
|
|
企业价值
30.55M
|
| 资产负债 |
|
每股账面净值
0.83
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
3.55M
|
|
每股收益
0.54
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphomaand pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS). |
